Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Polygenic Assessment and Testing of Heterogeneity and Subtypes in Type 2 Diabetes (PATHS-T2D): A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses

NCT07739537 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT07739537
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07739537 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Polygenic Assessment and Testing of Heterogeneity and Subtypes in Type 2 Diabetes (PATHS-T2D): A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses
Lead sponsor
Massachusetts General Hospital
Phase
Phase 4
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
September 30, 2030
Enrollment
100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diabete type 2, pharmacogenomic drug interaction